CB CAR-NK019 / Zhejiang University - LARVOL DELTA

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Enrolling by invitation ➔ Recruiting

Enrollment status • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/relapsed Central Nervous System Lymphoma (clinicaltrials.gov) - P1 | N=42 | Enrolling by invitation | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New P1 trial • CNS Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Anti-CD19 IL-10 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases (clinicaltrials.gov) - P=N/A | N=15 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2027 ➔ Jan 2027

Enrollment open • Trial completion date • ANCA Vasculitis • Genetic Disorders • Hematological Disorders • Immunology • Myositis • Scleroderma • Systemic Sclerosis • Vasculitis

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov) - P1 | N=48 | Enrolling by invitation | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting ➔ Enrolling by invitation | Trial completion date: Sep 2025 ➔ Dec 2026 | Trial primary completion date: Sep 2023 ➔ Dec 2025

Enrollment status • Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases (clinicaltrials.gov) - P=N/A | N=15 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New trial • ANCA Vasculitis • Genetic Disorders • Hematological Disorders • Immunology • Myositis • Scleroderma • Systemic Sclerosis • Vasculitis

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting ➔ Recruiting

Enrollment open • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New P1 trial • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19